Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belantamab mafodotin - GSK

Next Previous
Drug Profile

Belantamab mafodotin - GSK

Alternative Names: anti-BCMA-ADC - GSK ; Belamaf; belantamab mafodotin-blmf; blenrep; BLENREP; GSK'916; GSK-2857916; J6M0-mcMMAF

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Amgen; Atrium Health; GSK
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Multiple myeloma
  • Phase II Plasmablastic lymphoma

Most Recent Events

  • 13 Jun 2025 NICE recommends belantamab mafodotin for Multiple myeloma (Combination therapy, Second-line therapy or greater) in the United Kingdom
  • 13 Jun 2025 Hellenic Society of Hematology plans the phase II BONSAI trial for Idiopathic thrombocytopenic purpura (Treatment-experienced) in Greece (IV), in June 2025 (NCT07019545) (EUCT2023-509131-12-00)
  • 19 May 2025 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top